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Peeling the onion: the outer layers of Cryptococcus neoformans
Daniel P Agustinho, Liza C Miller, Lucy X Li, Tamara L Doering/+
Washington University School of Medicine, Department of Molecular Microbiology, St. Louis, Missouri, USA

Cryptococcus neoformans is an opportunistic fungal pathogen that is ubiquitous in the environment. It causes a
deadly meningitis that is responsible for over 180,000 deaths worldwide each year, including 15% of all AIDS-related
deaths. The high mortality rates for this infection, even with treatment, suggest a need for improved therapy. Unique
characteristics of C. neoformans may suggest directions for drug discovery. These include features of three structures
that surround the cell: the plasma membrane, the cell wall around it, and the outermost polysaccharide capsule. We review current knowledge of the fundamental biology of these fascinating structures and highlight open questions in the
field, with the goal of stimulating further investigation that will advance basic knowledge and human health.
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Cryptococcus neoformans is an opportunistic fungal
pathogen that causes severe infection of the central nervous system. Inhalation of this microbe, as either a spore
or desiccated yeast cell (Giles et al. 2009), causes a pulmonary infection that in immunocompetent individuals
is minimally symptomatic, although it may remain latent
for extended periods of time (Kwon-Chung et al. 2014,
Ballou and Johnston 2017). In severely immunocompromised individuals, however, C. neoformans can disseminate from the lungs and cross the blood-brain barrier
(Santiago-Tirado et al. 2017), causing an often-lethal meningoencephalitis. Close to 220,000 cases of cryptococcal meningitis are reported annually. These result in over
180,000 deaths worldwide, including 15% of all AIDSrelated deaths (Rajasingham et al. 2017). Mortality rates
range from 10 to 75% (Day et al. 2013, Jarvis et al. 2014),
even with carefully developed treatment regimens (Perfect et al. 2010), due to challenges that include drug toxicity, efficacy, cost, and availability. Increasing drug resistance has also been reported (Sionov et al. 2013, Chen et
al. 2015, Smith et al. 2015). Clearly, improved therapies
are needed to combat this infection.
The outer layers of C. neoformans have unique features
that may offer directions for drug discovery. These consist
of three concentric structures: the capsule, cell wall, and
plasma membrane (Fig. 1A, left). The outermost layer, the
polysaccharide capsule, is the hallmark of this organism
and is required for virulence. This highly dynamic structure modulates fungal interactions with immune cells.
Capsule components are also shed into the environment,
where they further influence the host response and may
be exploited for diagnosis and monitoring of cryptococcal infection (Alspaugh 2015). Both capsule thickness and
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shedding are tightly regulated in response to environmental
conditions (Kumar et al. 2011, Maier et al. 2015).
Below the capsule, and anchoring it, lies the fungal
cell wall. This complex structure surrounds the plasma
membrane and helps the cell withstand environmental
challenges such as osmotic and mechanical stress. It is
composed of glucans, chitin, chitosan, and glycosylated
proteins (Gow et al. 2017). Melanin pigment associated
with the cell wall further helps C. neoformans resist environmental stress and antifungal drug toxicity.
The innermost of the three layers we will consider
is the plasma membrane. Unique features of fungal
membranes are already the targets of several important
classes of antifungal drugs, the polyenes and azoles. The
plasma membrane is also the site of multiple proteins
implicated in fungal virulence and has been implicated
in the production of extracellular vesicles with potential
roles in virulence (Rodrigues et al. 2014, Brown et al.
2015, Joffe et al. 2016, Rella et al. 2016).
The unique features of the cryptococcal capsule, cell
wall, and plasma membrane demonstrate fascinating
fundamental biology that may potentially be exploited
for therapy. Below we review current knowledge of these
structures and their synthesis, and highlight some open
questions in the field. We do not address the regulation
of these structures in this short article, but refer interested readers to recent reviews that address this important
topic (Doering 2009, Gilbert et al. 2011, O’Meara and
Alspaugh 2012, Bahn and Jung 2013, Kwon-Chung et
al. 2014, Srikanta et al. 2014, Alspaugh 2015, Rella et al.
2016, Gow et al. 2017).
The capsule - The polysaccharide capsule is a major
cryptococcal virulence factor, which impedes the host immune response and is required for fungal survival within
the host. This structure is composed of two polymers,
glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal), along with trace mannoproteins
(Cherniak et al. 1998, Doering 2009). GXM, which typically has a molecular weight in the millions, consists of
an a-1,3-linked mannose backbone substituted with glucuronic acid and xylose (Cherniak et al. 1988, Cherniak et
online | memorias.ioc.fiocruz.br
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al. 1998, Heiss et al. 2009). GXMGal, roughly an order of
magnitude smaller, is a galactan with galactomannan side
chains bearing a variable number of xylose residues; the
galactose backbone also bears galactofuranose (all sugars
are pyranose where not specified) (Heiss et al. 2013, Previato et al. 2017). Mannose residues of both polymers may
also be O-acetylated (Gates-Hollingsworth and Kozel
2009, Previato et al. 2017). Based on analysis of shed
capsule, GXM constitutes ~90% of the capsule mass and
GXMGal the remainder (Cherniak and Sundstrom 1994),
although this may differ for surface-associated capsule.
The reactions that incorporate individual monosaccharides into complex polysaccharides like those of the
capsule or cell wall use activated sugar molecules, usually in the form of nucleotide sugars, as donors. These
compounds are mainly synthesized in the cytosol, although most glycan biosynthesis, including the formation of capsule polysaccharides (Yoneda and Doering
2006), occurs in the lumen of the secretory pathway.
For this to occur, the precursors must be moved into
the synthetic compartment by specific nucleotide sugar
transporters (NSTs) (Caffaro and Hirschberg 2006, Hadley et al. 2014). C. neoformans transporters have been
identified for all of the predicted capsule precursors:
GDP-mannose (Cottrell et al. 2007, Wang et al. 2014),
UDP-galactose (Cottrell et al. 2007, Moyrand et al. 2007,
Wang et al. 2014, Li et al. 2017), UDP-galactofuranose
(Li et al. 2018a), UDP-glucuronic acid (Li et al. 2018b),
and UDP-xylose (Li et al. 2018a).
Once nucleotide sugars are transported into the lumen of secretory organelles, they serve as substrates for
specific glycosyltransferases, which mediate the synthetic
reactions that form capsule polysaccharides. The complex
structures of GXM and GXMGal suggest the involvement
of multiple such enzymes. However, only a single glycosyltransferase, Cxt1, has been directly implicated in capsule synthesis. This β-1,2-xylosyltransferase is required
to produce fully xylosylated GXM and GXMGal (Klutts
et al. 2007, Klutts and Doering 2008). Two other cryptococcal glycosyltransferases have been biochemically
characterized (Sommer et al. 2003, Reilly et al. 2009,
Reilly et al. 2011), but only one of them has specificity
appropriate for a role in capsule production, and deletion
of the corresponding gene does not alter capsule composition (Sommer et al. 2003). It remains to be determined
whether this reflects the presence of compensating activities or indicates that this enzyme does not participate in
capsule synthesis. The many other activities required for
capsule synthesis (Bose et al. 2003, Klutts et al. 2006, Doering 2009) are likely encoded by some of the ~70 putative
glycosyltransferase genes observed in the C. neoformans
genome (Cantarel et al. 2009, Lombard et al. 2014); future
work will be required to identify them.
Most glycan synthetic machinery is localized to the
Golgi, where elaboration of core glycans on lipids and
proteins occurs and capsule is synthesized (Yoneda and
Doering 2006); Cxt1 also resides in this compartment
(Klutts et al., unpublished observations). From here, the
classical secretory pathway transports capsule material
to the cell surface (Yoneda and Doering 2006). There
are several models for the subsequent incorporation of

newly synthesized polysaccharides into the existing
capsule, which propose that this material is incorporated
either at its inner face, near the cell wall (Pierini and
Doering 2001, Cordero et al. 2013), or at the outer edge
of the structure (Zaragoza et al. 2006).
Although capsule polysaccharides are generally
described as linear polymers, they may also contain
branches, as suggested by their viscosity and shape factor (Cordero et al. 2011). Increased branching has been
reported to confer increased resistance to oxidative
stress, inhibit nitric oxide production by macrophages,
and enhance fungal survival in serum (Cordero et al.
2011). Interestingly, Cryptococcus liquefaciens, which
has a capsule that is chemically identical to that of C.
neoformans although with no evidence of branching, is
not as adept at resisting predation by amoeba, a potential
environmental host of Cryptococci (Araujo et al. 2012).
However, this difference in intracellular survival does
not hold in mammalian macrophages, suggesting that
the biological activity of capsular polysaccharide may be
context-dependent (Araújo et al. 2017) or other factors
may be involved. The details of branch formation and its

(A) Electron micrographs of Cryptococcus neoformans. Left, quickfreeze deep-etch image of cells grown in capsule-inducing conditions
(as in Haynes et al. 2011); right, transmission image of cells grown in
rich medium (YPD), which yields only thin capsules. C: capsule; W:
cell wall; PM: plasma membrane; M: mitochondrion; O: outer cell wall
layer; I: inner cell wall layer. (B) Fluorescent micrograph highlighting
the cell wall and capsule. Cryptococcal cells were induced to form capsule and stained with florescein (green) to label the cell wall and monoclonal antibody 2H1 (blue, generously provided by Arturo Casadevall)
to label the capsule, as in Pierini and Doering (2001). (C) Quick-freeze
deep-etch image highlighting the two layers of the cell wall.
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role in host-pathogen interactions are still unclear, but
promise to be exciting areas of study.
Mannoproteins comprise a small fraction of the capsule mass (Cherniak and Sundstrom 1994). These polypeptides appear mainly in the inner region of the capsule,
close to the cell wall (Jesus et al. 2010); they may represent an integral part of the capsule or perhaps secreted
proteins that are in transit through it. These predominantly cell wall proteins are discussed further below.
The cell wall - Moving inward from the capsule, the next
protective barrier that surrounds C. neoformans is the cell
wall (Fig. 1B). This structure is essential for cell viability,
because it protects the fungus from osmotic and other environmental stresses; it also serves as a scaffold for the capsule. The cell wall is composed of a- and b-linked glucans
(glucose polymers), chitin (a polymer of b-1,4-N-acetylglucosamine), chitosan (deacetylated chitin), glycoproteins,
and, in the presence of appropriate precursors, the pigment
melanin (Agustinho and Nosanchuk 2017). Because the
wall contains multiple components that are not shared with
mammalian hosts, it has been the focus of much research
for the development of antifungal compounds.
The cryptococcal cell wall is arranged in two layers.
In quick-freeze deep-etch electron micrographs the inner layer appears more striated and the outer one more
particulate (Fig. 1C); they also differ in electron density
on thin section electron micrographs (Fig. 1A, right).
The inner layer is composed of b-glucans and chitin;
mannoproteins and melanin are also most abundant in
this layer although they occur throughout the cell wall
(Vartivarian et al. 1989, Wang et al. 1995). The outer layer mainly contains a- and b-glucans (Reese et al. 2007).
Each of the wall components has a specific role in
maintaining cell wall structure and function. b-1,3-glucan
underlies the cell wall framework. It occurs as long polymers (James et al. 1990), with short b-1,6-glucan branches
that crosslink the polymers to each other, as well as to chitin and glycoproteins (Reilly and Doering 2009, Gilbert et
al. 2011, Gow et al. 2017). Chitin and chitosan contribute to
maintaining the integrity and flexibility of the wall structure (Banks et al. 2005), while chitin and chitooligomers
have been implicated in capsule architecture (Banks et al.
2005, Rodrigues et al. 2008, Fonseca et al. 2009). a-1,3glucans are required for tethering the polysaccharide capsule to the cell (Reese and Doering 2003, Reese et al. 2007).
Unlike capsule components, cell wall polysaccharides
are made at the plasma membrane and extruded through
it. Once outside the cell, they associate with each other
and with cell wall proteins that have exited via the secretory pathway. Some of these interactions are directed
by branching or cross-linking enzymes, which together
establish the complex wall structure (Gilbert et al. 2011,
Free 2013, Gow et al. 2017).
b-1,3-glucan is synthesized at the plasma membrane
from UDP-glucose by Fks1. The antifungal drug caspofungin (Kartsonis et al. 2003) targets Fks1 in other yeasts,
but notably is not effective against C. neoformans, even
though it inhibits the cryptococcal enzyme in vitro (Maligie and Selitrennikoff 2005). The synthases Skn1 and
Kre6 participate in formation of b-1,6-glucan, although
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their specific biochemical roles are not known; deletion of
the corresponding genes also perturbs capsular architecture, likely due to disorganization of the underlying cell
wall (Gilbert et al. 2010). Finally, a membrane-associated
alpha glucan synthase [Ags1; (Reese and Doering 2003)]
forms a-1-3-glucan.
Chitin is made at the plasma membrane by a family of chitin synthases. Although no individual family
member is essential for C. neoformans viability, the deletion of genes encoding chitin synthase 3 (Chs3) and a
chitin synthase regulator (Csr2) drastically impairs cell
wall integrity (Banks et al. 2005). Unlike in other fungi,
most of the chitin in C. neoformans is deacetylated to
form chitosan, a polymer that confers extra flexibility on
the cell wall. Cells from strains lacking all three chitin
deacetylases (Cda1, Cda2, and Cda3) have no cell wall
chitosan and exhibit defects in cell integrity (Baker et al.
2007). Chitosan is also essential for virulence (Baker et
al. 2011), a feature that has been successfully exploited
in using a chitosan-deficient strain of C. neoformans to
induce robust protective immunity in a murine model of
infection (Upadhya et al. 2016).
Another component of the cell wall that has been
implicated in virulence is melanin, a negatively-charged
polymeric and hydrophobic pigment made from phenolic
or indolic precursors (Nosanchuk and Casadevall 2006).
This material is associated with the cryptococcal cell wall
in a chitin-dependent manner (Baker et al. 2007, Camacho
et al. 2017). Melanization enhances cryptococcal survival
within natural predators, such as amoebae (Steenbergen
et al. 2001) or nematodes (Mylonakis et al. 2002). Disruption of its synthesis during infection reduces cryptococcal
dissemination (Noverr et al. 2004) and virulence (Salas
et al. 1996), possibly due to melanin-mediated inhibition of phagocytosis and modulation of host cell cytokine
responses (Huffnagle et al. 1995, Mednick et al. 2005).
Melanization also increases resistance to antifungal compounds such as amphotericin B and caspofungin (Wang
and Casadevall 1994a, Martinez and Casadevall 2006),
and to environmental stresses, including host oxidative
and nitrosative responses (Wang and Casadevall 1994b).
Many proteins are present in the cell wall, most of
them heavily modified with N- and O-linked glycans
(Klutts et al. 2006, Levitz and Specht 2006, Doering
2009, Reilly et al. 2011). The majority of these originate
as plasma membrane localized glycosylphosphatidylinositol (GPI)-linked polypeptides, which are transferred,
along with part of their anchor glycan, to covalent linkage with cell wall b-1,6-glycans (Orlean and Menon
2007, Muniz and Zurzolo 2014). Computational analysis predicts over 50 GPI-linked proteins encoded by the
cryptococcal genome (de Groot et al. 2005, Loftus et al.
2005, Levitz and Specht 2006); some of these have been
confirmed in studies of the C. neoformans secreted proteome (Eigenheer et al. 2007). Other proteins associate
with the cell wall via non-covalent interactions, linkage to b-1,3-glucan (Yin et al. 2008, Karkowska-Kuleta
and Kozik 2015, Gow et al. 2017), or disulfide bonds to
polypeptides that are themselves covalently bound to
structural glycans (de Nobel and Lipke 1994, Jaafar et
al. 2003); these processes are less well studied.
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Multiple cell wall proteins have key functions in cryptococcal biology. Some have been implicated in the dynamic responses of the wall to environmental conditions,
such as the GPI-linked b-glucanase Gas1 that acts in
b-1,3-glucan remodeling (Levitz and Specht 2006, Eigenheer et al. 2007). Another important GPI-linked protein
is phospholipase B1 (Plb1), which has been implicated in
C. neoformans virulence (Siafakas et al. 2007, Maruvada
et al. 2012). Cell wall mannoproteins, small amounts of
which can be found in the capsule (see above), are often
80-90% mannose by mass (Mansour and Levitz 2003).
They are highly immunogenic (Levitz and Specht 2006,
Wozniak and Levitz 2009) due to their activation of the
mannose receptor on dendritic cells and consequent activation of T-cells, which leads to a protective immune response against C. neoformans (Specht et al. 2007, Dan et
al. 2008a, Dan et al. 2008b). These proteins are being explored as an adjuvant component of a vaccine for cryptococcosis (Chow and Casadevall 2011, Levitz et al. 2015).
Several cryptococcal mannoproteins have been studied in depth. The first one described, MP98, was shown
to be involved in T-cell activation (Levitz et al. 2001)
and turns out to be the same protein as the chitin deacetylase Cda2 discussed above (Gilbert et al. 2012). This
protein, despite originating as a GPI-anchored membrane protein, associates with the cell wall in a manner
that is independent of its GPI structure and b-1,6-glucans; the enzymatic activity is associated with the membrane form (Gilbert et al. 2012). Other mannoproteins
that have been studied include MP88, involved in T-cell
activation (Huang et al. 2002), and others (MP84 and
MP115) that have homology to chitin deacetylase and
carboxylesterase proteins (Biondo et al. 2005). MP84
has been reported to mediate adhesion of C. neoformans
yeasts to lung epithelial cells, suggesting a role early in
infection (Teixeira et al. 2014). Finally, the mannoprotein Cig1 participates in iron uptake and contributes to
virulence in a mouse model (Jung et al. 2006, Cadieux et
al. 2013). Future studies of these and other cell wall proteins will further illuminate the synthesis and function
of this complex structure, and may also advance efforts
to develop vaccines or therapies.
Plasma membrane - Beneath the polysaccharide capsule and cell wall is the plasma membrane (Fig. 1), which
serves as a barrier to the passage of hydrophilic molecules
(van der Rest et al. 1995). Fungal membranes are composed of sterols, glycerophospholipids, and sphingolipids
(Ejsing et al. 2009, Singh et al. 2017), although these differ in many respects from their mammalian counterparts.
The plasma membrane also contains proteins, which
maintain their association with the membrane via transmembrane domains, GPI anchors, or various lipid modifications (Santiago-Tirado and Doering 2016). Membrane
structure and composition are dynamic, and vary with the
fungal species analyzed and the environmental conditions
(Singh and Prasad 2011, Xia et al. 2011).
Fungal membranes differ from those of mammals in
containing ergosterol in place of cholesterol. This feature has been exploited by two major classes of antifungal drugs, Amphotericin B, which binds ergosterol, and

the azoles, which inhibit its synthesis. C. neoformans
also produces glycosylated ergosterols, termed sterylglycosides (SGs) (Weete et al. 2010, Rella et al. 2016). Although the enzyme(s) responsible for SG synthesis has
not been identified (Warnecke et al. 1999), a glucosidase
involved in SG degradation (termed EGCrP2 or Sgl1)
is known. Deletion of the corresponding gene yields
growth arrest, abnormal budding, and abnormal vacuole
morphology (Watanabe et al. 2015); it also eliminates
virulence in a murine model (Rella et al. 2015). Interestingly, inoculation with this mutant protected mice
against subsequent lethal doses of C. neoformans H99
and Cryptococcus gattii R265 (Rella et al. 2015).
Yeast glycerophospholipids resemble those of higher
eukaryotes, although their fatty acid composition may
vary, while glycosphingolipids are more distinct. One
of the latter that has been studied in detail in C. neoformans is glucosylceramide (GlcCer) (Nimrichter and
Rodrigues 2011), which influences cryptococcal pathogenicity and is required for normal growth, resistance to
alkaline conditions, spore production, and germination
(Del Poeta et al. 2014). GlcCer is formed by the enzyme
glucosyl-ceramide synthase 1, which transfers glucose
from the nucleotide sugar UDP-glucose to a ceramide
backbone (Rittershaus et al. 2006, Rella et al. 2016);
disruption of the corresponding gene abrogates growth
and virulence (Rittershaus et al. 2006). Notably, fungal
GlcCer differs from that of other eukaryotes by the presence of a methyl group in the sphingoid base (Rodrigues
et al. 2000). Eliminating this methylation alters membrane integrity and reduces virulence (Singh et al. 2012,
Raj et al. 2017). Little is known about GlcCer catabolism, but a cryptococcal glucosylceramidase (EGCrP1)
may act in GlcCer quality control (Ishibashi et al. 2012).
Within the plasma membrane of eukaryotes, distinct
microdomains are enriched in ergosterol, GlcCer, other
sphingolipids, and GPI-proteins. Such ‘lipid rafts’ are
also found in C. neoformans, although they contain more
saturated fatty acids (e.g. palmitic and stearic acid), fewer unsaturated fatty acids (e.g. oleic and linoleic acid),
and none of the very long chain fatty acids (> 20 carbons) found in lipid rafts from mammalian cells and S.
cerevisiae (Siafakas et al. 2006). Several virulence factors cluster in these domains, including the phospholipase Plb1 (Maruvada et al. 2012), the antioxidant Cu/
Zn superoxide dismutase (Siafakas et al. 2006), and the
plasma membrane ATPase (Pma1) (Farnoud et al. 2014).
Final thoughts - The AIDS epidemic allowed the explosive emergence of opportunistic pathogens such as C.
neoformans. The death toll caused by this fungus continues to be an enormous burden, especially in regions
with limited health care resources. This impact, coupled
with the challenges of drug cost, availability, toxic side
effects, lengthy treatment regimens, and resistance, creates an urgent need for improved therapies.
C. neoformans is protected by concentric surface
structures, each of which influences multiple aspects of
pathogenesis. Unique features of these structures may offer targets for new antifungal agents, but many of them
remain poorly defined. For capsule, we still do not know
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how GXM and GXMGal are arranged and associate with
the cell, or most of the glycosyltransferases required
for their synthesis. The mechanisms of capsule branching, shedding, and degradation also remain unexplored.
Fungal cell wall synthesis is fairly well understood and
has been successfully exploited for antifungal therapy
by glucan synthase inhibitors, but this class of drugs is
not effective against cryptococcal infection. Continued
exploration of wall synthesis and regulation, and of cell
wall proteins or strains defective in cell wall components
that may act as vaccines, may help compensate for this
gap in efficacy. Finally, the plasma membrane is the site
of unique glycolipids whose synthesis and catabolism is
yet to be fully elucidated; these and novel membrane proteins may offer targets for drug development or potential
for diagnostics. Addressing these many fascinating questions, as we peel away the layers of this fascinating yeast,
should lead to advances in fundamental biology and point
the way to new ways to combat a formidable pathogen.
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